In a turbulent market environment, SLXN, also known as Moringa Acquisition Corp, has seen its stock price plummet to a 52-week low, reaching a concerning $1.82. With a market capitalization of just $2.99 million and a weak financial health score according to InvestingPro, the company faces significant challenges. This significant downturn reflects a staggering 1-year change, with the company's stock value eroding by -98.04%. Investors are closely monitoring SLXN as it navigates through these challenging financial waters, with the hope for a strategic turnaround that could potentially rejuvenate the stock's performance in the upcoming months. InvestingPro analysis reveals high price volatility, with 7 additional key insights available to subscribers.
In other recent news, Silexion Therapeutics Corp has announced a 1-for-9 reverse share split of its ordinary shares, a strategic move approved by shareholders. This development consolidates the company's issued and outstanding ordinary shares, increasing the par value of each share. Additionally, Silexion has made adjustments to its outstanding warrants, decreasing the number of ordinary shares issuable upon warrant exercise and increasing the exercise price to $103.50 per share.
In the clinical development arena, Silexion has made significant progress in its preclinical studies for SIL-204, a siRNA candidate aimed at treating KRAS-driven cancers. It is preparing to move into Phase 2/3 clinical trials in the first half of 2026. The company also reported improved results from its Phase 2 trial of LODER™ in treating locally advanced pancreatic cancer.
Finally, Silexion announced the immediate resignation of board member Ilan Shiloah due to time constraints. This leaves vacancies on the audit, compensation, and corporate governance and nominating committees. These are the latest developments in the ongoing corporate evolution of Silexion Therapeutics Corp.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.